17. A method of producing an antibody specific for picornavirus conformational epitopes, the method comprising:

immunizing at least one non-human mammal with at least one empty immature picornavirus particle comprising at least two viral proteins of the picornavirus to form at least one B cell specific for the picornavirus;

selecting at least one B cell specific to the picornavirus;

fusing the selected B cell with at least one immortalized cell to produce at least one hybridoma, wherein the hybridoma is capable of producing at least one antibody or a fragment thereof specific for the picornavirus; and

optionally isolating the antibody from the hybridoma and sequencing the variable heavy and light chains.

18. The method according to claim 17, wherein the immature picornavirus particle comprises a precursor for at least one viral protein of the picornavirus.

19. The method according to any one of claims 17 or 18, wherein the picornavirus may be selected from the group consisting of Aphthovirus, Aquamavirus, Avihepatovirus, Cardiovirus, Cosavirus, Dicipivirus, Enterovirus, Erbovirus, Hepatovirus, Kobuvirus, Megrivirus, Parechovirus, Salivirus, Sapelovirus, Senecavirus, Teschovirus, and Tremovirus.

20. The method according to any one of claims 17-19, wherein the picornavirus is selected from the group consisting of Enterovirus A, Enterovirus B, Enterovirus C, Enterovirus D, Enterovirus E, Enterovirus F, Enterovirus G, Enterovirus H, Enterovirus J, Rhinovirus A, Rhinovirus B, and Rhinovirus C.

21. The method according to any one of claims 17-20, wherein the picornavirus is EV71.

22. The method according to claim 21, wherein the at least two viral proteins are selected from the group consisting of VP0, VP1, VP2, VP3, and VP4.

23. The method according to claim 21 or 22, wherein the at least two viral proteins comprise VP2 and VP3.

24. The method according to any one of claims 21 to 23, wherein the precursor is VP0.

25. An isolated nucleic acid molecule encoding

(a) at least one variable light chain of the antibody or a fragment thereof defined in any one of claims 1-3, 8 and 9, wherein the variable light chain comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 3 and 16-18, a variant, mutant or fragment thereof; and

(b) at least one variable heavy chain of the antibody or a fragment thereof defined in any one of claims 1-3, 8 and 9, wherein the variable heavy chain comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 5 and 19-22, a variant, mutant or fragment thereof.

26. The isolated nucleic acid molecule according to claim 25, wherein the at least one nucleic acid sequence in (a) has at least 90% sequence identity to SEQ ID NO: 10 and/or 24 and/or 25 and/or26; and/or

the at least one nucleic acid sequence in (b) has at least 90% sequence identity to SEQ ID NO: 11 and/or 12 and/or 27, and/or 28 and/or 29 and/or 30.

27. The isolated nucleic acid molecule according to claim 26, comprising:

(a) at least one nucleic acid sequence from the group consisting of SEQ ID NOs: 10 and 24-26, a mutant, variant or fragment thereof; and/or

(b) at least one nucleic acid sequence from the group consisting of SEQ ID NOs: 11, 12, and 27-30, a mutant, variant or fragment thereof.

28. An isolated nucleic acid molecule encoding

(a) at least one variable light chain of the antibody or a fragment thereof defined in any one of claims 4, 5, 8 and 9, wherein the variable light chain comprises at least one amino acid sequence selected from the group consisting of SEQ ID NOs: 1 and 15, a variant, mutant or fragment thereof; and

(b) at least one variable heavy chain of the antibody or a fragment thereof defined in any one of claims 4-5, 8 and 9, wherein the variable heavy chain comprises at least one amino acid sequence of SEQ ID NO: 2, a variant, mutant or fragment thereof.

29. The isolated nucleic acid molecule according to claim 28, wherein the at least one nucleic acid sequence in (a) has at least 90% sequence identity to SEQ ID NO: 8 and/or 23; and/or

the at least one nucleic acid sequence in (b) has at least 90% sequence identity to SEQ ID NO: 9.

30. The isolated nucleic acid molecule according to claim 29, comprising:

(a) at least one nucleic acid sequence of SEQ ID NO: 8 and/or 23, a mutant, variant or fragment thereof; and/or

(b) at least one nucleic acid sequence of SEQ ID NO: 9, a mutant, variant or fragment thereof.

31. An isolated nucleic acid molecule encoding

(a) at least one variable light chain of the antibody or a fragment thereof defined in any one of claims 6-9, wherein the variable light chain comprises at least one amino acid sequence of SEQ ID NO: 6, a variant, mutant or fragment thereof; and

(b) at least one variable heavy chain of the antibody or a fragment thereof defined in any one of claims 6-9, wherein the variable heavy chain comprises at least one amino acid sequence of SEQ ID NO: 7, a variant, mutant or fragment thereof.

32. The isolated nucleic acid molecule according to claim 31, wherein the at least one nucleic acid sequence in (a) has at least 90% sequence identity to SEQ ID NO: 13; and

the at least one nucleic acid sequence in (b) has at least 90% sequence identity to SEQ ID NO: 14.

33. The isolated nucleic acid molecule according to claim 32, comprising:

(a) at least one nucleic acid sequence of SEQ ID NO: 13, a mutant, variant or fragment thereof; and

(b) at least one nucleic acid sequence of SEQ ID NO: 14, a mutant, variant or fragment thereof.

34. An expression vector comprising at least one of isolated nucleic acid molecule defined in any one of claims 25 to 33.

35. A host cell comprising the expression vector defined in claim 34.

36. A kit comprising at least one antibody or fragment thereof defined in any one of claims 1-9.